Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

Mepolizumab added to triple therapy improves exacerbation outcomes in moderate to severe COPD and is effective to 2 years of treatment.

The study evaluated 807 adults who initiated an anti–IL–5 therapy (79% mepolizumab, 21% benralizumab) between 2017 and 2020.

Physical therapy may be an effective treatment for some patients with neurogenic thoracic outlet syndrome. A physical therapist prescribes exercises to strengthen and stretch your back muscles. These ...

Triple therapy for COPD is more likely to offer cardiopulmonary benefits vs dual therapy, as indicated by NNT estimates for key cardiac outcomes.

OrthoCincy physical therapy manager. Neltner said stretching the neck may be one of the best ways to turn around TOS. “Thoracic outlet syndrome is basically compression of either nerves or ...

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of ...

Thoracic imaging is critical in detecting ... (NSCLC), there may be an opportunity for a patient to receive targeted therapy or immunotherapy, depending on if the patient meets the criteria ...

The big question for you and your doctor: Is it so hard to breathe that you need oxygen therapy? This treatment gives you extra oxygen so that breathing is easier and you stay more active.